Northern Trust’s Atrium Therapeutics RNA Stock Holding History

Northern Trust’s Portfolio RNA Stock Details RNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.61M	Buy	119,781 +21,196	+22%	+$277K	﹤0.01%	3258
2026 Q1	$1.32M	Buy	+98,585	New	+$1.39M	﹤0.01%	3197

Other funds holding RNA

Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CRCM LP San Francisco, California $152M AUM 26.3% 1-Year Est. Return

TAL

TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Northern Trust's RNA Position: Q2 2026 in Review

Northern Trust increased its Atrium Therapeutics (RNA) stake by 22% in Q2 2026, buying an estimated $277K and bringing the position to 119,781 shares worth $1.61M. The position accounts for ﹤0.01% of the portfolio, ranked #3258.

Northern Trust first reported a position in RNA in Q1 2026 and has held it in 2 quarters since. 155 funds tracked by Wall St. Rank hold RNA as of Q2 2026.

Northern Trust held 119,781 shares of Atrium Therapeutics worth $1.61M as of Q2 2026.
Northern Trust bought 21,196 Atrium Therapeutics shares in Q2 2026, an estimated $277K.
Atrium Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #3258 holding.
Northern Trust first reported a position in Atrium Therapeutics in Q1 2026 and has held it in 2 quarters since.
155 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.